Attention!

What is the drug POTARBIN®

POTARBIN® is a powerful inhibitor of many tyrosine kinases for oral administration, including tyrosine kinases of vascular endothelial growth factor (VEGFR) -1, -2, -3 receptors; platelet growth factor (PDGFR)receptors-α and-β; fibroblast growth factor (FGFR) receptors -1 and -3; stem cell factor receptor (Kit), as well as interleukin 2-induced T-cell kinase(Itk); leukocyte-specific proteintyrosine kinase (Lck) and macrophage colony stimulating factor receptor tyrosine kinase (c-Fms).

Dosage form

Dosage 200 mg: Round biconvex tablets, covered with a film-coated pink color with a brownish tinge. The core of the tablet is white to almost white in color.

Dosage 400 mg:  Round biconvex tablets coated with a white film coating. The core of the tablet is white to almost white in color.

Indications for use

Treatment of advanced renal cell carcinoma (RCC).

Treatment of advanced soft tissue sarcoma (SMT) (excluding gastrointestinal stromal tumors and liposarcoma) in patients who have previously received chemotherapy.

Efficacy and safety studies

In accordance with current legislation, the drug has proven its effectiveness, safety and quality during state registration. For registration purposes, a bioequivalence study was conducted with the original (reference) medicinal product.